Seattle Biotech Firm Impel NeuroPharma Files for $75M IPO

Impel NeuroPharma (Impel), a Seattle-based biotech company led by Adrian Adams, has indicated the company plans to go public. According to GeekWire, Impel filed paperwork for a $75 million IPO. Impel would be the first Washington company to go public in 2021 via a traditional IPO. To date, Impel has raised $140 million.

Known for its Precision Olfactory Delivery (POD) platform, developed by John Hoekman, Impel has developed a drug that helps treat migraines, which is currently going through FDA approvals.